Literature DB >> 22367010

Irreversible electroporation for focal ablation at the porta hepatis.

Veeru Kasivisvanathan1, Ankur Thapar, Youssof Oskrochi, John Picard, Edward L S Leen.   

Abstract

Patients with chemotherapy-refractory liver metastases who are not candidates for surgery may be treated with focal ablation techniques with established survival benefits. Irreversible electroporation is the newest of these and has the putative advantages of a nonthermal action, preventing damage to adjacent biliary structures and bowel. This report describes the use of irreversible electroporation in a 61-year-old man with a solitary chemoresistant liver metastasis unsuitable for radiofrequency ablation as a result of its proximity to the porta hepatis. At 3 months, tumor size was decreased on computed tomography from 28 × 19 to 20 × 17 mm, representing stable disease according to the response evaluation criteria in solid tumors. This corresponded to a decrease in tumor volume size from 5.25 to 3.16 cm(3). There were no early or late complications. Chemoresistant liver metastases in the proximity of the porta hepatis that are considered to be too high a risk for conventional surgery or thermal ablation may be considered for treatment by the novel ablation technique of irreversible electroporation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22367010     DOI: 10.1007/s00270-012-0363-7

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  8 in total

1.  Risk of local failure after ultrasound guided irreversible electroporation of malignant liver tumors.

Authors:  Robert M Eisele; Sascha S Chopra; Matthias Glanemann; Bernhard Gebauer
Journal:  Interv Med Appl Sci       Date:  2014-12-22

2.  Percutaneous Ablation of Hepatic Tumors at the Hepatocaval Confluence Using Irreversible Electroporation: A Preliminary Study.

Authors:  Tiankuan Li; Wei Huang; Zhiyuan Wu; Yong Wang; Qingbing Wang; Ziyin Wang; Qin Liu; Jingjing Liu; Shenjie Wang; Xiaoyi Ding; Zhongmin Wang
Journal:  Curr Oncol       Date:  2022-05-31       Impact factor: 3.109

3.  Patterns of complications following intraoperative radiofrequency ablation for liver metastases.

Authors:  Grégoire Desolneux; Jeremy Vara; Tsiriniaina Razafindratsira; Milène Isambert; Véronique Brouste; Pippa McKelvie-Sebileau; Serge Evrard
Journal:  HPB (Oxford)       Date:  2014-05-15       Impact factor: 3.647

4.  The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.

Authors:  W van den Bos; D M de Bruin; B G Muller; I M Varkarakis; A A Karagiannis; P J Zondervan; M P Laguna Pes; D P Veelo; C D Savci Heijink; M R W Engelbrecht; H Wijkstra; T M de Reijke; J J M C H de la Rosette
Journal:  BMJ Open       Date:  2014-10-29       Impact factor: 2.692

5.  Severe complications with irreversible electroporation of the pancreas in the presence of a metallic stent: a warning of a procedure that never should be performed.

Authors:  Christopher Månsson; Anders Nilsson; Britt-Marie Karlson
Journal:  Acta Radiol Short Rep       Date:  2014-12-03

6.  Radiological findings of porcine liver after electrochemotherapy with bleomycin.

Authors:  Maja Brloznik; Nina Boc; Gregor Sersa; Jan Zmuc; Gorana Gasljevic; Alenka Seliskar; Rok Dezman; Ibrahim Edhemovic; Nina Milevoj; Tanja Plavec; Vladimira Erjavec; Darja Pavlin; Masa Bosnjak; Erik Brecelj; Ursa Lampreht Tratar; Bor Kos; Jani Izlakar; Marina Stukelj; Damijan Miklavcic; Maja Cemazar
Journal:  Radiol Oncol       Date:  2019-10-10       Impact factor: 2.991

7.  Novel irreversible electroporation ablation (Nano-knife) versus radiofrequency ablation for the treatment of solid liver tumors: a comparative, randomized, multicenter clinical study.

Authors:  Xiaobo Zhang; Xiao Zhang; Xiaoyi Ding; Zhongmin Wang; Yong Fan; Guang Chen; Xiaokun Hu; Jiasheng Zheng; Zhixiao Xue; Xiaofeng He; Xin Zhang; Yingtian Wei; Zhongliang Zhang; Jing Li; Jie Li; Jie Yang; Xiaodong Xue; Li Ma; Yueyong Xiao
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

Review 8.  Focal therapy for prostate cancer: rationale and treatment opportunities.

Authors:  V Kasivisvanathan; M Emberton; H U Ahmed
Journal:  Clin Oncol (R Coll Radiol)       Date:  2013-06-04       Impact factor: 4.126

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.